Allon Therapeutics Wins National Biotech Award
Advertisement
Allon Therapeutics Inc. announced it will receive the Gold Leaf Award as the Early Stage Company of the Year (Health) from BIOTECanada, Canada’s national biotechnology industry organization. The award will be presented on June 28 at 4PM at the BIO 2011 International Convention in Washington, D.C.
BIOTECanada said Allon was chosen as the top pre-commercialization company in the Canadian biotechnology healthcare sector “by distinguishing themselves from their peers with demonstrated technology innovation and achieved milestones.”
Gordon McCauley, Allon’s President and CEO, said the prestigious Gold Leaf Award recognizes the Company’s clinical trial successes and progress toward commercializing products in devastating degenerative brain diseases, such as Alzheimer’s, Parkinson’s and several types of frontotemporal dementia.
“Being chosen as Canada’s leading pre-commercial healthcare biotech company is a great honour and an enormous compliment to the dedication, innovation, and excellence demonstrated by our team every day,” said McCauley. “It is also important recognition of the investigators, patients, and caregivers we partner with to find solutions to these awful diseases.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
In the heat of the wound - Smart bandage
Sartorius opens new Center of Excellence for bioanalytics in Ann Arbor - Manufacturing of instruments, consumables and reagents for cell and protein analysis
CyBio and Macherey-Nagel collaborate to develop applications for automated DNA/RNA preparation
Innovations for Health: When Molecular Spectroscopy Meets Lasers and Photonics - "An all-optical, minimally invasive and label-free diagnostic tool could represent a significant advance in health..."
HI viruses crack the lock to the cell nucleus - For the first time, researchers have observed how HIV penetrates the nuclear pores to the genome of human immune cells
Closure of Astellas CNS research in Edinburgh
Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections
New method for measuring luminescence lifetime offers breakthrough in scientific imaging - Accelerating the pace of discovery in science and industry
Decreasing biodiversity may promote spread of viruses - New insight into the dynamics of infectious disease
Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies - Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors
3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!
